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Like vaccines, biologic proteins can be very immunogenic for reasons including route of administration, dose
frequency and the underlying antigenicity of the therapeutic protein. Because the impact of immunogenicity
can be quite severe, regulatory agencies are developing risk-based guidelines for immunogenicity screening.
T cell epitopes are at the root of the immunogenicity issue. Through their presentation to T cells, they activate
the process of anti-drug antibody development. Preclinical screening for T cell epitopes can be performed in
silico, followed by in vitro and in vivo validation. Importantly, screening for immunogenicity is complicated
by the discovery of regulatory T cell epitopes, which suggests that immunogenicity testing must now take
regulatory T cells into consideration. In this review, we address the application of computational tools for
preclinical immunogenicity assessment, the implication of the discovery of regulatory T cell epitopes, and
experimental validation of those assessments.
© 2009 Elsevier B.V. All rights reserved.
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1. Introduction
The biotechnology revolution has made great strides in recent
years: drug developers are producing novel therapeutic proteins,
including monoclonal antibodies (mAbs) and antibody-like protein
scaffolds. However, in the push to deliver novel biologics to the
market, developers have on occasion overlooked factors that may
contribute to protein immunogenicity, with sometimes disastrous
results. Depending on the therapeutic context, autologous or human-
like proteins have proven to be surprisingly immunogenic, suggesting
that assumptions about immune tolerance also require careful
consideration in biologics design.
Fortunately, years of thorough study of the parameters inﬂuencing
vaccine immunogenicity and efﬁcacy now allow parallels to be drawn
for protein therapeutics. Factors such as delivery route and vehicle,
formulation, dosing, innate immune system activation, and the ability
of the protein to interface with the humoral (B cell) and cellular
(T cell) immune systems, may all inﬂuence the potential immuno-
genicity of proteins to some degree, whether these proteins are
administered for therapeutic purposes (as in enzymes, monoclonals,
replacement proteins) or as vaccines [1].
Both cellular and humoral immune responses may result from
therapeutic protein administration, similar to the effect of vaccines.
Anti-drug antibodies (ADA)may neutralize the therapeutic effects of a
drug and/or alter its pharmacokinetics. T cells are certainly involved in
this immune response when IgG class ADA are observed, because
antibody isotype switching is a key function of T-dependent antigens
[2]. Serious adverse events can be provoked if the ADA cross-react
with a critical autologous protein. Two examples of undesirable ADA
responses include autoimmune thrombocytopenia (ITP) following
exposure to recombinant thrombopoietin [3], and pure red cell
aplasia, which was associated with a particular formulation of
erythropoietin (Eprex) [4]. Since the effects of immunogenicity can
be quite severe, regulatory agencies are developing risk-based guide-
lines for immunogenicity screening [5].
T cell epitope content is one of the factors that contributes to
antigenicity. The binding strength of T cell epitopes to major
histocompatibility complex (MHC or HLA) molecules is a key
determinant in T cell epitope immunogenicity. This allows the
epitopes with higher binding afﬁnities to be more likely to be
displayed on the surface of the cell (in the context of MHC molecules)
where they are recognized by their corresponding T cell receptor
(TCR) [6]. Thus, the fate of a protein drug may be determined by its
constituent 9-mers and their corresponding HLA binding afﬁnities.
Fortunately, after years of development and validation, T cell epitopes
can now be predicted relatively accurately using in silico tools. As a
result, immunoinformatics tools are now being applied to triage
protein therapeutics into higher risk and lower risk categories prior to
clinical development based on their T cell epitope content. Therefore,
ﬁnding peptide sequences that may trigger or alternatively suppress a
T cell response may be the most important step to be taken in the pre-
clinical development of a protein drug.
One approach to measuring the potential immunogenicity of a
protein is to parse protein sequences into overlapping 9-mer peptide
frames, and to search for potential T cell epitopes by estimating the HLA
binding potential of these short sequences, in silico, to eight common
class II HLA alleles that “cover” the majority of human genetic
backgrounds [7]. A critical step in this process is to use an algorithm
that normalizes HLA allele-speciﬁc scores in order to be able to compare
scores of any 9-mer across multiple HLA alleles [8]. Approaches that do
not normalize across alleles are highly likely to over-predict for selected
HLA, thereby skewing the analysis and reducing its accuracy. The
potential immunogenicity of a protein can thenbe representedasa “sum
of the scores” for the overlapping 9-mer peptide frames, and the
potential for any single peptide sequence to be immunogenic can be
estimated from its cumulative HLA binding score.
Applying this approach to both biologics (usually autologous
proteins such as monoclonals) and foreign proteins, we have
discovered that the in silico signature, or binding score, of a T cell
epitope tends to be within one to two deviations from the mean of a
set of random protein sequences. This allows relatively accurate
prediction of potential T cell epitopes. However, knowledge of
potential HLA binding does not translate into knowledge of the type
of T cell response that may ensue. Potentially, effector (inﬂammatory)
or regulatory (suppressive) T cell immunity may be activated. This
complicates the process of screening for immunogenicity. The
presence of T cell epitopes may contribute to immunogenicity, but is
not in itself sufﬁcient. The controlling factor appears to be the
“context” in which a T cell epitope is recognized by a T cell. If signals
evoke release of inﬂammatory cytokines, resulting in expression of co-
stimulatory factors by antigen-presenting cells, an effector immune
response is triggered. In the absence of such signals, and the presence
of others (such as an abundance of IL-2, or other regulatory cytokines
such as TGFβ), a T cell may be deviated towards a regulatory or
tolerogenic response. Thus, for protein biologics, a T cell epitope may
be friend (regulatory) or foe (effector) depending on the context of
the response (Fig. 1). This is an important observation, as it turns out.
Regulatory T cell epitopes may be a key feature of biologic drugs, but
their existence and their role in the immune response to biologics is
not yet well understood.
1.1. Immunogenicity factors: foreignness, T cell epitope content,
“danger signal”
Tolerance to self-proteins is an integral aspect of the immune
system, without which immune response would be severely ham-
pered or dangerous to “self”. Despite the importance of tolerance to
the regulation of auto-reactive immune responses, it is quite clear that
tolerance can be overcome, and that T cell epitopes contribute to the
induction of immune response to autologous proteins. There aremany
parallels between the development of autoimmune disease and
immunogenicity of therapeutic proteins, including the reduction of
regulatory T cell (Treg) immune responses and induction of T effector
responses [9]. Deviation of the immune response away from tolerance
towards immunogenicity probably involves B cells, effector T cells, and
danger signals such as toll-like receptor ligands.
Since tolerance is considered the normal state of immune response
to autologous proteins, the development of ADA to recombinant
autologous proteins can be regarded as a “breach” of tolerance. Auto-
reactive B cells are found in normal individuals, but such cells are
rarely stimulated to produce antibodies by circulating levels of native
proteins. The presence of low levels of circulating antibodies against
autologous proteins is a well-known phenomenon in drug develop-
ment, but these auto-antibodies rarely interfere with the drug. In
contrast, the presence of cell responses to autologous proteins are a
critical determinant of autoimmune disease; they also contribute to
the development of higher levels of anti-self antibodies by providing
cytokine “help” to B cells [10].
How does immune response to autologous proteins occur? In
theory, T and B cell receptors to “self” are eliminated in the course of
immune maturation in the thymus (T cells) and the bone marrow
(B cells). However, there is evidence that auto-reactive T cells are
present in the peripheral circulation. Thymic deletion of self-reactive T
cells is imperfect. 25–40% of auto-reactive T cells escape into the
periphery because of low avidity [11,12], absence of thymic expression,
inefﬁcient expression or inefﬁcient processing of T cell epitopes [13].
This has been documented in diabetes [14], rheumatoid arthritis [15]
and multiple sclerosis [16]. Tolerance to self can be overcome if a
danger signal [17] is present, or if cross-reactivity between self
epitopes and epitopes of pathogens triggers an effector immune
response against self (e.g. human coronavirus [18] and lyme disease
antigen [19]). The importance of danger signals to the development of
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T effector responses to autologous proteins is worth bearing in mind,
since many protein therapeutics are produced using methods that
may incorporate such signals at levels that are below the usual limits
of detection. Another factor that may play a role in the induction of
autoimmunity is known as “heterologous immunity” or T cell
response to epitopes that cross-react with self [20]. Unfortunately,
the role of heterologous immunity in the development of ADA to
protein therapeutics remains unexplored at present, even though it is
likely to be a contributing factor.
In the context of B cell response, the development of antibodies
(including auto-antibodies) can be T-independent or T-dependent.
Although T cell independent (Ti) antibody development is often noted
as a source of antibodies to protein therapeutics, Ti activation of B cells
generally does not lead to antibody afﬁnity maturation or to B cell
memory. More commonly, T cell dependent (Td) activation of B cells is
triggered, leading to a robust antibody response, afﬁnity maturation,
isotype switching, and the development of B cell memory. The
induction of IgG class ADA, whether to chimeric antibodies, human
antibodies, recombinant proteins, or proteins of non-human origin,
normally implies that some of the sequences in the protein triggered a
T cell response that led to a Td B cell response, and thus, isotype
switching [21].
The source of a danger signal may be quite different for vaccines
and biologic proteins. Vaccine adjuvants contain innate immune
system triggers such as Complete Freund's Adjuvant and CpG
oligodeoxynucleotides. These adjuvants are examples of toll-like
receptor (TLR) ligands. TLRs are pattern recognition receptors
expressed by antigen-presenting cells that recognize structurally
conserved molecular patterns in microbes such as LPS, bacterial DNA
and certain bacterial polysaccharides [22]. Protein therapeutics, as a
rule, are highly puriﬁed proteins that do not contain danger signals,
but the process of manufacturing may lead to introduction of TLR
ligands, or, alternatively, some components of the formulation may
degrade in the course of drug processing and formulation, leading to
the formation of a danger signal (see, for example, the discussion on
Eprex below).
In summary, three critical factors contribute to immune response
to protein therapeutics. First, B cells must recognize protein antigens
in their native form using the B cell receptor (membrane bound
immunoglobulin). Second, B cells or other antigen-presenting cells
(APC) must process and present T cell epitopes derived from the
protein therapeutic, triggering a T cell response. Third, a danger signal
is required to create the proper “context” for triggering a T cell
response. Regardless of the initial trigger, immune response to protein
drugs, whether antibodies or recombinant human proteins such as
FVIII, erythropoietin, and myozyme, is due to the combined activities
of T and B cells that recognize antigen and the presence of a danger
signal “trigger”.
1.2. Types of T cell responses (effector and regulatory)
While T cells begin on a path to maturation in the thymus, their
fate is only reached in the periphery. That process begins when naïve T
cells engage epitope-loaded MHC at the surface of antigen-presenting
cells through the T cell receptor. A series of molecular events ensues,
resulting in differential expression of functional and phenotypic
markers that make it possible to experimentally distinguish one T cell
type from another [23]. Stimulatory and inhibitory responses are
mediated by effector and regulatory T cells, respectively. In general,
effector T cells produce an inﬂammatory response to clear infections,
whereas regulatory T cells generate a suppressive response that
promotes immunological tolerance.
1.2.1. T helper effector cells
Effector T cells fall into two broad classes: T helper cells (Th) and
cytotoxic T lymphocytes (CTLs). Phenotypically, these populations are
distinguished by cell surface proteins; Th cells express CD4 and CTLs
CD8. Th cells orchestrate events critical to both the humoral and
cellular arms of the adaptive immune system. They prime naïve CTL
and B cell responses, generate secondary responses and contribute to
the induction and sustainability of immune memory [24]. T helper
(CD4+) T cells are critically important instigators of ADA response.
The Tcell receptor (TCR) assures immune response speciﬁcity through
interaction with epitope-loaded MHC on antigen-presenting cells
(APCs). TCRs are as pleiomorphic as B cell receptors (immunoglobu-
lin). In the case of CD4+ T cells, the TCR recognizes MHC class II
molecules that are expressed by dendritic cells, macrophages or B
cells.
Anti-drug immune responses commence with ingestion of the
protein drug by APCs such as dendritic cells or B cells. Foreign antigens
are taken up by APCs into endocytic vesicles where proteases degrade
proteins into peptides. Endosomes then fuse with MHC class II-
containing vesicles (MIIC vesicles) enabling peptides to bind to MHC
molecules. In a concentration-dependent manner, and aided by HLA-
DM, peptides compete for binding in the MHC groove. Peptide–MHC
complexes are transported to the cell surface for presentation to
T cells.
Naïve CD4+ T cells that have a TCR that binds to the MHC class II–
epitope complex are activated with co-stimulatory interaction
between CD80/CD86 and CD28 (signals T1 and T2 in Fig. 2a). TCR
activation switches on downstream signaling pathways in T cells that
lead to secretion of IL-2. This cytokine, in turn, stimulates further
intracellular signaling by binding in an autocrine fashion to the IL-2
receptor, which leads to T cell proliferation [25]. Activated CD4+ Th
cells secrete a wide range of cytokines, including interferon-gamma
(IFN-γ), IL-4 and IL-17, the hallmark cytokines of themajor Th lineages
Th1, Th2 and Th17, respectively [26].
Although commitment to a particular T cell subset is not
necessarily ﬁxed and is currently the subject of intense investigation,
the function of the classic Th1, Th2, Th17 and Treg subsets is well-
described. Th1 cells activate macrophages and aid in the expansion of
CTLs. Th2 cells aid in the adaptive humoral response by triggering B
cells to produce antibodies (signals B2 and B3 in Fig. 2a). T cells that
secrete IL-17, the third and newest major Th lineage, are pro-
inﬂammatory and important in pathogen defense [27]. Interestingly,
Th17 cells can be induced to become regulatory T cells, further
underscoring the ﬂexibility of CD4+ T cell subsets (and their T cell
epitope-speciﬁc immune responses) to exhibit different phenotypes,
depending on the context of the immune response [28]. T helper cells
that secrete IL-2 play an important role in the development of B
Fig. 1. The same T cell epitope may trigger an effector immune response, characterized
by inﬂammatory cytokines, up regulation of B cell activity, and development of anti-
drug antibodies, or a regulatory T cell response characterized by suppressor cytokines,
decreased cellular proliferation, and decreased antibody secretion. The “context” of the
immune response is the most important factor that determines the T cell phenotype.
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memory cells. In the absence of T help (and IL-2), B cells do not
expand, afﬁnity mature, or isotype switch [29] (Fig. 2a, b).
Dysfunctional or inappropriate responses elicited by T cells can
give rise to a number of disease conditions. For example, inappropriate
responses associated with Th2 cells give rise to allergic diseases, and
inappropriate responses associated with Th1 or Th17 cells may result
in autoimmune diseases [25]. Again, the T cell response is not
fundamentally deﬁned by the epitope; rather, the phenotype is
determined by the environment in which the epitope is presented in
to the T cell.
1.2.2. Regulatory T cells
Regulatory or “suppressor” T cells are key players in the complex
set of interactions that regulate immune responses to ensure tolerance
to self. There are two types of tolerance: central and peripheral.
Central T cell tolerance occurs during thymic development, when T
cells that have high afﬁnity TCR for autologous epitopes are deleted. B
cells that can recognize self-proteins may similarly be deleted in the
bone marrow. In addition, peripheral tolerance mechanisms exist to
control autoimmunity and prevent auto-reactivity after lymphocytes
have exited the thymus or bone marrow. According to current
thinking, auto-reactive T cells with moderate afﬁnity may escape
deletion and be converted to function as ‘natural’ regulatory T cells
(nTreg) to suppress autoimmunity [30]. Tolerance in the periphery is
characterized by plasticity of T cell lineage commitment, where
mature T cells are converted to a Treg phenotype upon activation
through their T cell receptor in the presence of IL-10 and TGF-β. The
role of these ‘adaptive’ Treg (aTreg) cells may be to dampen effector
immune responses either to control a vigorous pro-inﬂammatory
immune reaction to infection or possibly to facilitate co-existence
with beneﬁcial symbiotic bacteria and viruses [31,32]. Tregs exhibit a
CD4+CD25+FoxP3+ phenotype; these proteins are important to
Fig. 2. a and b. Stimulation of T helper (Th) cells by antigens involves ﬁrst activation by interleukin 1 (IL-1) (T1) and then presentation of the antigen at the surface of antigen-
presenting cells (usually macrophages, dendritic cells or B cells) (T2) in associationwith class II major histocompatibility complexmolecules (MHC II); for extrinsic (foreign) proteins
this requires initial capture of the protein, followed by denaturation and/or degradation so as to associate the molecule or fragments with MHC II. T cells stimulated in this way
express receptors for interleukin 2 (IL-2), and secrete various molecules, including factors which stimulate B cells to divide and/or secrete Ig, interferon-gamma and IL-2. (B1) In turn,
IL-2 causes proliferation of Th and cytotoxic/suppressor T cells. Encounter of the same antigen by a B cell results in processing and presentation of the epitope at the B cell surface in
the context of MHC (B1). Co-stimulatory factors such as B7 interact with the memory B cell (B2), resulting in the secretion of cytokines by the T cell (B3). These cytokines allow the B
cell to mature and become a dedicated IgG-producing (isotype switched) memory B cell (B4).
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maintaining tolerance as attenuated CD25 and FoxP3 expression is
associated with autoimmune disease [33,34].
The major function of regulatory T cells is to regulate T cell-
mediated immunity and suppress auto-immunogenic T cells that were
not destroyed during their development in the thymus. This is
extremely important to help prevent autoimmune diseases. Tregs are
promoted by the transforming growth factor-beta (TGF-β) by leading
to the induction of FoxP3 expression, which in turn renders the T cell
suppressive function [35]. Tregs secrete speciﬁc cytokines that have a
suppressing effect on effector response. IL-2 is a cytokine that is
important for T cell proliferation. It contributes to signal transduction
in Tregs and the maintenance of homeostasis and competitive
ﬁtness of natural Treg cells [35]. Stimulating CD4+ cells with antigen
in vitro in the presence of TGF-β has led to the induction of FoxP3
expression. However, following re-stimulation with antigen in the
absence of exogenous TGF-β, most cells seem to lose the FoxP3
expression [35].
IL-35 is a cytokine produced only by regulatory T cells, which plays
a role in maximizing suppressive activity of immune cells [36].
Conversely, IL-4 and IFN-γ have been shown to play repressive roles in
FoxP3 transcriptional activity [35], which drives T cell fate determina-
tion away from the Treg lineage.
Studies in animal models of autoimmunity have also shown an
increased frequency or severity of autoimmunity in the absence of Tregs
[37,38] and that transfer of Treg cells is sufﬁcient to protect from or
reverse autoimmunity. Also, antigen-speciﬁc inducible T regulatory cells
that express FoxP3 stably may generate transplantation tolerance,
preventing or aiding autoimmunity, allergy and inﬂammation [32].
1.3. Deﬁnition of T cell epitopes
While B cells and antibodies generally recognize conformational
epitopes from surface proteins, T cells recognize linear epitopes
derived from proteins that are processed by APCs. As described above,
antigenic (and autologous) proteins are broken down by proteolytic
enzymes in the APC. During this process very large numbers of peptide
fragments are produced. Any one of these fragments could be a T cell
epitope, but only about 2% of all the fragments generated have the
right amino acid side chains that allow them to bind in the MHC
binding groove and be presented on the surface of the APC. One of the
critical determinants of immunogenicity is the strength of T cell
epitope binding to MHC molecules [39]. Peptides binding with higher
afﬁnity to MHC are more likely to be displayed on the cell surface
where they can be recognized by TCRs. Both T effectors and Treg have
TCR that bind to MHC–peptide complexes; as far as can be
determined, it is the nature of the T cell (Treg or T effector) that
determines the overall effect of the T cell responses; the T cell epitope
sequence and its afﬁnity for MHC does not appear to differ between T
cell types.
1.4. Immunoinformatic identiﬁcation of T cell epitopes
Over the last decade, researchers have developed a number of
computer algorithms that map the locations of MHC class I- and class
II-restricted T cell epitopes within proteins of various origins. Some in
silico methods include frequency analysis, support-vector machines,
hidden Markov models, and neural networks. For recent reviews of T
cell epitope-mapping tools, see Sette [40], Brusic [41] and De Groot
[42] among others. What these tools have in common is an ability to
quickly screen large volumes of protein sequences for putative T cell
epitopes. This preliminary screen reduces the search space dramati-
cally, typically by at least 20-fold. MHC class II prediction methods are
useful for the evaluation of Td immunogenicity, as MHC class II-
restricted T cells provide help to B cells, leading to the development of
ADA.
Such in silico predictions of T helper epitopes have already been
successfully applied to the design of vaccines [43,44] and to the
selection of epitopes in studies of autoimmunity [45]. The authors use
the EpiMatrix system,which has been validated followingmore than a
decade of use for in vitro and in vivo studies (e.g. [46–50]). EpiMatrix
employs HLA class I and class II “pocket proﬁles” that describe HLA
pocket binding coefﬁcients, and applies these coefﬁcients to the
prediction of overlapping 9- and 10-mer peptide epitopes. Each
frame-by-allele evaluation is considered a single “assessment.” All
EpiMatrix assessment scores (Z-scores) equal to or above 1.64 are
deﬁned as “Hits”; that is to say potentially immunogenic and worthy
of further consideration. A sample analysis is provided in Fig. 3 below.
The EpiMatrix report provided in Fig. 3 illustrates an important
concept about T cell epitopes — those that are the most immunogenic
tend to have more than oneMHC or HLA binding motif. Another way to
say this is that the best T cell epitopes tend to contain “clusters” of HLA
bindingmotifs and clustering is highly correlatedwith immunogenicity.
We have found that T cell epitope “clusters” range from 9 to roughly 25
amino acids in length and, considering their afﬁnity to multiple alleles
and across multiple frames, can contain anywhere from 4 to 40 binding
motifs. A cluster score is calculated by summing the EpiMatrix scores for
each of the eight class II alleles. Cluster scores higher than 10 are
considered to be signiﬁcant. Further, we have noticed that many of the
most reactive T cell epitope clusters are concentrated in a single 9-mer
frame, a featurewe refer to as anEpiBar. As shown in Fig. 3, an EpiBar is a
Fig. 3. The inﬂuenza HA peptide 306–318 is an epitope known to be promiscuously immunogenic. It has high Z-scores for all 8 alleles in EpiMatrix. The ranking of the EpiMatrix scores
(by color) is shown in the Z-score legend. Peptides that have predicted Z-scores above 1.64 (approximately the top 5% of all 9-mers derived from any given protein) have a signiﬁcant
chance of binding to MHC molecules and scores above 2.32 (approximately the top 1%) are highly likely to bind to MHC molecules. A cluster score is calculated by summing the
EpiMatrix scores for each of the eight class II alleles. Cluster scores higher than 10 are considered to be signiﬁcant. The inﬂuenza HA peptide shown here has a cluster score of 18. The
band-like pattern (EpiBar) showing “hits” for potential binding for all eight class II alleles is characteristic of promiscuous epitopes.
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single 9-mer framewhich is predicted to bind at least four different HLA
alleles. Sequences that contain EpiBars include inﬂuenza hemagglutinin
307–319 (cluster score of 18), tetanus toxin 825–850 (cluster score of
16), and GAD65 557–567 (cluster score of 19). The signiﬁcance of
promiscuous binding is underscored by its association with immuno-
dominance as illustrated for several proteins including tetanus toxin
[51], inﬂuenza hemagglutinin [52], hepatitis B virus nucleocapsid
antigen [53], hepatitis C virus nonstructural protein 3 [54] and HIV
proteins gag and nef [55].
To consider the overall immunogenic potential of a whole protein,
EpiMatrix Z-scores are summed for all “Hits” and adjusted for the
length of the protein. By testing a large number of randomly generated
protein sequences, an expected value of zero can be determined (the
average score for a random protein sequence) and all other protein
sequences can be compared to that standard (Fig. 4). Proteins scoring
in the top quartile of the distribution (roughly speaking all proteins
scoring above 20) contain an unusually high number of potential T cell
epitopes. This method is described in a number of publications, most
recently in De Groot et al. Clinical Immunology 2009 [56]. Importantly,
the presence of one or more dominant T cell epitope clusters can
enable signiﬁcant immune responses to otherwise low-scoring
proteins. Therefore, any evaluation of immunogenic potential should
consider not only overall potential but also regional potentials.
1.4.1. T cell epitope prediction: a retrospective analysis
T cell epitope-mapping tools such as EpiMatrix [57] can be highly
accurate predictors of immune response. So as to illustrate the predictive
capabilities of EpiMatrix, we have recently analyzed a set of highly
immunogenic peptide epitopes that are included in a commercial reagent
(CEFT produced by PANATecs) commonly used as a positive control in
immunological tests such as ELISPOT or cytokine ﬂow cytometry. As
shown in Table 1, we analyzed all 23 epitopes in the CEFT reagent, which
had previously been identiﬁed as promiscuous epitopes [58]. This
peptide pool contains eight HLA Class II-restricted peptides from
inﬂuenza virus, eight from Epstein-Barr virus, six from tetanus toxin
and one from the human cytomegalovirus (Table 1). The CEFT reagent is
immunogenic as measured by IFN-γ release (in ELISpot) or proliferation
(in CFSE assays) [58]. It contains peptides restricted by the eight
archetypal Class II alleles used for epitope prediction with EpiMatrix
(DRB1⁎0101, DRB1⁎0301, DRB1⁎0401, DRB1⁎0701, DRB1⁎0801,
DRB1⁎1101, DRB1⁎1301, and DRB1⁎1501).
CEFT peptide sequences were evaluated using the EpiMatrix panel
of Class II predictive matrices based on estimated probabilities of MHC
binding. The resulting Z-scores again fall on a common scale that can
be directly compared across HLA alleles (Table 1). Nearly all of these
well-known T cell epitopes have clusters of immunogenic potential
and EpiBars. The correspondence with EpiMatrix prediction is very
high: seventeen (17) of the twenty peptides included in the CEFT
reagent, or 85%, were correctly predicted to bind to each of their
speciﬁed alleles, using EpiMatrix. The negative predictive value of
EpiMatrix (NPV) was calculated to 94%.
As illustrated by the CEFT analysis, based on the “immunogenicity
score” of a peptide sequence [42], it is possible to make an informed
decision about the likelihood that the peptide sequence will provoke
an immune response. As shown in the next section, we have used the
EpiMatrix immunogenicity scale to prospectively predict the clinical
immunogenicity of a novel “peptibody” and a bioengineered auto-
logous protein [59,60].
1.4.2. T cell epitope prediction: a prospective analysis
In silico screening along with ex vivo immunogenicity testing has
been used to evaluate protein therapeutics in preclinical development.
Two examples of correctly predicted clinical immunogenicity protein
therapeutics include FPX and GDNF, which were subsequently
published [3,59]. FPX is a recombinant fusion protein consisting of
two identical, biologically active peptides linked to human Fc
fragment. EpiMatrix predicted a strong signal for immunogenicity
within the 14-amino acid carboxy-terminal region of the peptide
portion of FPX. With administration of FPX in 76 healthy human
subjects, 37% developed antibodies after a single injection. A memory
T cell response against the carboxy-terminus of the peptide was
observed in antibody positive subjects but not in antibody negative
subjects. The predicted promiscuity of the predicted T cell epitope(s)
was conﬁrmed by representation of all common HLA alleles in
antibody positive subjects. HLA-haplotype DRB1⁎0701/1501 was
predicted to be associated with the highest T cell and antibody
response; this was conﬁrmed in T cell and antibody assays. Tatarewicz
and Moxness also used EpiMatrix to screen GDNF, a protein
therapeutic that was subsequently proven to be immunogenic in
clinical trials [46]. The protein contains epitope clusters that rank as
high as well-known immunogenic epitopes on the EpiMatrix
immunogenicity scale (Fig. 5) [46].
Several other publications have also linked Tcell epitopes, immune
response and immunogenicity. For example, Barbosa et al. [61]
conﬁrmed the role of T cells in the immune response to Betaseron
by linking ADA to HLA-DR type. In addition to the two published
studies [60,46], in silico assessments have been predictive of clinical
immunogenicity in at least two unpublished studies (Vibha Jawa
personal communication [62]).
2. Tcell epitope contribution to immunogenicity to foreign antigens
2.1. Presence of T cell epitopes correlates with antibody response to
foreign proteins
T help and cytotoxic T cell response are required to enhance the
efﬁcacy of vaccines against viruses. The importance of T cell help is
nowhere more obvious than for inﬂuenza vaccines. Conventional
inﬂuenza vaccines are designed to stimulate a protective antibody
response to hemagglutinin (HA). Even though T cell help is required for
Fig. 4. Summary of the immunogenicity “scale” ﬁndings for selected autologous
proteins shows how antibody sequences rank, compared to standard controls.
EpiMatrix protein immunogenicity scores higher than 20 are considered to be
potentially immunogenic. Note that the low-scoring proteins on the lower left side of
the scale are known to engender little to no immunogenicity while the higher scoring
proteins on the upper left side of the scale are all known immunogens. For monoclonal
antibodies, we adjust the antibody scores for the presence of pre-deﬁned regulatory
T cell epitopes [6] as we have evidence that the presence of these epitopes decreases the
overall immunogenicity of antibodies in the clinic. Discovering these peptide sequences
and identifying putative T cell epitopes may potentially be the most important aspect
for protein therapeutic development.
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Table 1
EpiMatrix analysis of the CEFT peptide pool.
(continued on next page)
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high speciﬁc IgG antibody titers against the HA antigen [63], antibody
titers are usually relatively weak and do not last very long. Induction of
CD4+ T cell response to inﬂuenza Th cell epitopes improves antibody
response against B cell epitopes and generates long-term memory
[64,65]. The live-attenuated inﬂuenza vaccine (LAIV) is much more
immunogenic, suggesting that better-conserved T cell epitopes present
in the internalﬂu proteins that are present in the LAIV [66] contribute to
the immunogenicity of the vaccine. Therefore, the presence of T cell
epitopes is critically important for the induction of B cell response, and
particularly B cell memory, against foreign antigens.
2.2. Epitope density contributes to enhanced immunogenicity of
foreign proteins
We have found that T cell epitopes containing a higher concentra-
tion of putative MHC binding motifs per amino acid tend to be more
immunogenic. Presumably, this is due to the ability of these epitopes
to be effectively processed by APCs and presented on a range of
different MHC molecules (since more than one binding motif is
present), thereby triggering a range of CD4+ T cell clones, leading to a
synergistic effect. We have numerous examples from our vaccine
research. For example, the EpiMatrix epitope-mapping algorithmwas
used to identify highly promiscuous T cell epitopes within the
predicted secreted proteins from the F. tularensis tularensis genome
as well as from known expressed proteins. Peptide epitopes were
tested in ELISpot assays using blood from human subjects that had
recovered from F. tularensis tularensis infection. ELISpot assays showed
positive IFN-gamma responses to 21 of 25 individual Class II peptides
and to peptide pools, in most human subjects [67]. Although
differences in the HLA restriction of the molecules contributes to
subject variability, these MHC binding motif-rich epitopes are
generally highly immunogenic, leading to a 93% overall positive
response rate in our vaccine programs.
2.3. Absence of T cell epitopes corresponds to lower immunogenicity of
foreign proteins
The inability of a speciﬁc HLA molecule to present epitopes from a
given vaccine antigen is well known to be a cause of vaccine failure.
For example, Celis et al. reported that a signiﬁcant number of HBsAg-
reactive T cells from various HBV-immune individuals recognize a
determinant localized near the amino terminus of HBsAg [68,69] and
individuals who cannot present the T cell epitopes in this region are
unable to mount a protective immune response following vaccination
[70,71]. In this example, the lack of a T cell epitope to provide help to
the B cells led to a lower antibody response.
2.4. Abrogation of T cell epitopes diminishes immunogenicity
Lack of T help and the consequent abrogation of B cell response
contribute to the idea that deliberate removal of T cell epitopes might
reduce immunogenicity [72]. One of the ﬁrst deimmunized proteins
was “Sakstar” or stapylokinase [73]. Modiﬁcation or removal of the
speciﬁc amino acids that contribute to HLA binding led to a reduction
in the potential of epitope to stimulate T cell response. Similarly, a
number of epitope-abrogation studies have been performed using
FVIII. Jones et al. identiﬁed a 15-mer sequence in human FVIII that
bound strongly to DRB1⁎0401, ⁎1101, and ⁎1501, moderately to ⁎0701,
weakly to ⁎0101, and not at all to ⁎0301 and ⁎1301 in HLA Class II
binding assays. They then modiﬁed the sequence of this epitope to
reduce its potential to bind to HLA. The modiﬁed peptide did not bind
to any allele and was less immunogenic in vitro [74,75].
3. The regulatory T cell epitope wrinkle
Using EpiMatrix, we screened human antibody sequences for HLA
binding sequences.We discovered seven epitope clusters conserved in
human antibodies, each containing at least one EpiBar. These
sequences are derived from the Fc region and from the framework
regions of variable domains. Because EpiMatrix successfully identiﬁes
regions which code for T cell activation, conservation of these epitopes
CEFT peptides receiving a high score (N2.32) are indicated in black; peptides receiving a moderate score (1.64–2.31) are dark grey; and peptides scoring in the top 10% of scores are
in light grey. Three (3) of the twenty-three (23) CEFT peptides included in the reagent (CEFT#18, 20, and 21) are not shown above because HLA do not belong to the “standard” set
of eight archetypal alleles (DRB3⁎0201, DRB1⁎1001, and DQ2). CEFT# 19 was given a score in the top 10% for its speciﬁed allele of DRB1⁎0301, which would normally not be
interpreted as a signiﬁcant binder for DR3, yet an EpiBar is present within the sequence, illustrating its potential to be a strong candidate as a promiscuous epitope.
Table 1 (continued)
Fig. 5. This ﬁgure shows the EpiMatrix immunogenicity scale to prospectively predict
clinical immunogenicity. It compares novel protein sequences to proteins of known
varying immunogenic potential. The new protein therapeutic GDNF was about to be
used as treatment for Parkinson's disease or amyotrophic lateral sclerosis (ALS). In
EpiMatrix analysis, however, it scores as high as published highly immunogenic
peptides from inﬂuenza hemagglutinin and tetanus toxin. This might be the cause for
the observed side effects during its clinical use as therapeutic.
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suggests that they play an important immunological role. Typically,
we screen proteins for immunogenicity but we realized that these
putative binders may in fact be tolerizing. In other words, these
EpiMatrix results can be interpreted to mean that antibody sequences
are presented to T cells to stimulate Tregs rather than effector T cells.
These regulatory T cell epitopes (Tregitopes), when co-incubated with
a target antigen, induce bystander tolerance, which could explain the
relatively lower immunogenicity of humanized antibodies. Indeed, we
found that the immunogenicity of therapeutic monoclonal antibodies
is correlated to their Tregitope content (R-square 0.7, p=.002), a
ﬁnding of direct relevance to the biologics industry [6]. Fig. 6
illustrates the hypothesized mechanism of Tregitope-mediated
immunosuppression. A major implication of this concept is that
other autologous proteins may also contain regulatory T cell epitopes.
As therapeutics, these proteins will interface with the immune system
and their regulatory and effector epitopes will be presented to T cells.
Therefore, regulatory T cell epitopes must also be accounted for when
addressing protein immunogenicity.
4. Current Applications of T cell epitope mapping to
biologics development
4.1. Screening for T cell epitopes and de-immunization
The use of cytokines, growth factors, and monoclonal antibodies in
clinical settings is often associated with the development of
antibodies directed against therapeutic proteins. Therefore, diminish-
ing the immunogenicity of therapeutic proteins without hindering
their function may improve clinical outcomes [72]. Epitope mapping
and evaluation of the potential for immunogenicity on an “immuno-
genicity scale” is one approach; the same tools can be used to identify
clusters of epitopes for removal. As described previously, reduction in
T cell epitope content has been associated with reduced immuno-
genicity. This can be accomplished by substitution of key amino acids
in the T cell epitope sequences which abrogate binding to HLA and
thereby attenuate epitope potential to trigger a Tcell response. Altered
T cell epitopes no longer bind to HLA. Therefore, uncovering the
immunogenic regions and speciﬁc amino acid residues involved in
binding to HLA can allow protein therapeutics developers to abrogate
T-dependent antibody responses, reducing the immunogenicity of
their candidate drug. Such epitope-modiﬁcations are easily evaluated
in vitro and in vivo prior to release of the protein therapeutic for
clinical development. This method of reducing immunogenicity, also
known as de-immunization, is described in detail in [72].
4.2. Consideration for regulatory T cell epitopes
AlthoughTcells that are auto-reactive are said to bedeleted in thymic
development, somemayescape deletion and cause prospective epitopes
in autologous proteins to trigger T cells. However, not all T cell epitope
clusters can be considered to be potentially immuno-stimulatory. As
discussed above, some T cells speciﬁc for autologous proteins escape
thymic deletion and become natural regulatory T cells (Tregs); they
appear to serve as regulators or suppressors of auto-reactive immune
responses [30]. Therefore, epitopes that induce Treg responses might be
useful to down-regulate immune responses in the context of protein
therapeutics and autoimmune disease. Tregs have been shown to
suppress auto-antibodies and thus they may also play a role in the
suppressionofADA [9,76].WehavedevelopedaTregepitope(Tregitope)
adjusted EpiMatrix score for monoclonal antibodies to predict anti-
therapeutic antibody response by deducting the scores of Tregitopes
from the EpiMatrix raw score. In our experience adjusted scores are
better correlated to the observed clinical immune response. This scoring
protocol enables categorization of antibodies into four groups: 1) low
Tregitope and high T effector (neo epitope) content; 2) low Tregitope
and low neo epitope content; 3) high Tregitope and low neo epitope or
4) high Tregitope content and high neo epitope content (Table 2).
Antibodies with low epitope content and antibodies which contain
only regulatory epitopes, such as Nuvion and Synagis, would be less
likely to induce T cell-mediated immune responses than antibodies
containing high numbers of effector epitopes and low numbers of
regulatory epitopes, such as Rituxan. These predictions appear to
correlate with the observed immunogenicity of these drugs in the
clinic [77]. In some cases high numbers of regulatory epitopes can
silence immune responses to antibodies containing high numbers of
effector epitopes, such as may be the case with Humira (Table 2).
To address immunogenicity concerns related to low Tregitope
content in antibodies, targeted sequence modiﬁcations may be made
by site-directed mutagenesis to enrich for Tregitopes. Alternatively,
when structure/function considerations preclude the mutagenesis
approach, Tregitopes may be engineered at the carboxy-terminus of
the heavy and/or light chains, far from the antigen binding region.
This approach could also be adopted to reduce immunogenicity of
other classes of protein therapeutics.
4.3. Alternative methods for reducing immunogenicity
Other means of improving the safety and efﬁcacy of biologics by
reducing their immunogenicity include humanization and PEGylation.
Following FDA approval of the ﬁrst therapeutic monoclonal antibodies
(mAb), many were found to elicit anti-drug antibodies in immune-
competent patients [78–81]. For example, OKT3, an immunosuppres-
sive drug used to treat transplant rejection and the ﬁrst monoclonal
antibody approved for human use, elicited antibodies in 86% of
patients [82]. Not surprisingly, in hindsight, the explanation for
immunogenicity was patient response to foreign (mouse) sequences.
To improve the next generation of mAbs, constant domain sequences
of antibody light and heavy chains were replaced by human constant
regions to produce chimeric antibodies. This approach met with
mixed success because chimeric antibodies still raised human anti-
Fig. 6. We have discovered conserved T cell epitopes in IgG that engage natural
regulatory T cells. We hypothesize that antibody-derived Treg epitopes (dark blue
epitope on the top) activate regulatory T cells, which leads to suppression of effector T
cells that recognize effector epitopes (red epitope on the bottom), like those of IgG
hypervariable regions to which central tolerance does not exist. Whether this
suppression is mediated by regulatory cytokines alone or by contact-dependent
signaling, or both, has yet to be determined [95]. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
Analysis of anti-therapeutic antibody responses in relation to neo epitope and Tregitope
content.
Monoclonal antibodies High Tregitope content (%) Low Tregitope content (%)
Low neo epitope content Nuvion (0) Synagis (1)
High neo epitope content Humira (12) Rituxan (27)
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mouse antibodies against the mouse variable regions. While an
improvement over fully murine monoclonals, chimeric antibodies
were shown to raise varying immune responses depending on their
target and their indication. For example, Rituximab, a chimeric anti-
CD20 antibody, elicited no immune response from B cell chronic
lymphocytic leukemia patients [83,84] but was immunogenic in 27%
of Sjogren's syndrome and 65% of systemic lupus erythomatosus
patients [85,86]. Later, monoclonal antibodies were further huma-
nized by graftingmouse CDR regions onto a human scaffold so that the
only mouse sequences to remain were those that encode antigen
speciﬁcity. Remarkably, some of these antibodies are still immuno-
genic. For example, Campath-1H (Alemtuzumab), a humanized
monoclonal antibody that targets human CD52 expressed in many
lymphoid neoplasms, has been shown to be immunogenic in N60% of
rheumatoid arthritis patients [87–89]. Indeed, a completely human
antibody sequence also does not guarantee immune stealth. 17% of
rheumatoid arthritis and Crohn's disease patients receiving Humira
(Adalimumab), a tumor necrosis factor alpha (TNF-α) inhibitor,
developed anti-drug antibodies [90,91]. The immunogenicity of this
antibody has been linked to the presence of ﬁve to seven key T helper
epitopes as deﬁned by a number of different laboratories (Fiona
Harding, Philip Stas, Matt Baker, personal communication).
PEGylation, the conjugation of polyethylene glycol (PEG) to a
biologic, has also been used to reduce immunogenicity. PEGylation
leads to an increase in protein solubility and hydrodynamic size,
allowing a therapeutic protein to evade renal clearance and increase
its circulatory time in the body. The large size of the PEG molecules
may interfere with antibody binding [92]. PEGylation has been used
successfully to minimize the immunogenicity of therapeutic enzymes
such as arginase, asparaginase and purine nucleoside phosphorylase,
because it blocks antibody binding but does not prevent the diffusion
of small molecule substrates [93,94].
5. Summary
Integrating T cell epitope-mapping tools into scientiﬁc research
saves time and promises to increase the safety and efﬁcacy of protein
therapeutics. As with all bioinformatics tools, in vitro and in vivo
conﬁrmations of in silico observations are necessary; validated T cell
epitope-mapping tools can then be used with more conﬁdence to
begin new scientiﬁc explorations [95].
A number of therapeutic protein developers have already incorpo-
rated in silico, ex vivo and in vivo preclinical immunogenicity screening
protocols into their product development strategy. Mapping epitopes
that are contained in recombinant autologous and therapeutic proteins
may allow their identiﬁcation and subsequent modulation, thereby
reducing the chance that a biologicwill induce a Tcell-mediated immune
response. T cell epitopes should not all be considered dangerous — in
some cases, T cell epitopes can be associated with a regulatory T cell
response. Regulatory T cells have the potential to help develop and
maintain tolerance. Enhanced use of T cell epitope-mapping tools may
improveourability to identify Tcell epitope “friends” (Treg epitopes) and
“foes” (effector epitopes) in the context of protein therapeutics and
autoimmunity and enable us to harness these important mediators of
immune response. Effective differentiationbetweenTcell epitope friends
and foeswill facilitate development of less immunogenic therapeutics to
smooth progress towards improved human health outcomes.
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